Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ocular Therapeutix (OCUL) EPS (Basic) (2016 - 2026)

Ocular Therapeutix has reported EPS (Basic) over the past 14 years, most recently at -$0.4 for Q1 2026.

  • For Q1 2026, EPS (Basic) fell 5.26% year-over-year to -$0.4; the TTM value through Mar 2026 reached -$1.44, down 26.32%, while the annual FY2025 figure was -$1.42, 16.39% down from the prior year.
  • EPS (Basic) for Q1 2026 was -$0.4 at Ocular Therapeutix, down from -$0.27 in the prior quarter.
  • Over five years, EPS (Basic) peaked at -$0.01 in Q3 2023 and troughed at -$0.49 in Q1 2024.
  • A 5-year average of -$0.29 and a median of -$0.28 in 2024 define the central range for EPS (Basic).
  • Biggest five-year swings in EPS (Basic): skyrocketed 96.77% in 2023 and later plummeted 2100.0% in 2024.
  • Year by year, EPS (Basic) stood at -$0.2 in 2022, then plummeted by 75.0% to -$0.35 in 2023, then rose by 20.0% to -$0.28 in 2024, then grew by 3.57% to -$0.27 in 2025, then tumbled by 48.15% to -$0.4 in 2026.
  • Business Quant data shows EPS (Basic) for OCUL at -$0.4 in Q1 2026, -$0.27 in Q4 2025, and -$0.38 in Q3 2025.